Adagene Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Adagene Inc
Access all reports
Adagene Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based cancer immunotherapies. The company utilizes its proprietary technology platforms, including its Dynamic Precision Library (DPL) and SAFEbody technology, to engineer therapeutic antibodies with unique functional epitopes. These technologies enable the development of innovative monoclonal antibodies that target various cancers, aiming to improve both safety and efficacy. Adagene's product pipeline includes several candidates in various stages of clinical and preclinical development. The company is actively engaged in both mono and combination therapies, exploring new approaches to treat solid tumors and other cancer types.The company is headquartered in Suzhou, China, and its shares are listed on the NASDAQ.
Latest articles
The Art of Portfolio Management: Lessons from Tom O'Hara
Tom O'Hara shares insights on stock picking, navigating market distractions, and the importance of one-on-one meetings with management teams.
4 Oct 2024
The Samsung Co-CEOs: Jong-Hee Han & Young-Hyun Jun
Samsung Electronics' dual-CEO structure, led by Jong-Hee Han and Young-Hyun Jun, is designed to navigate the complexities of its diverse business.
3 Oct 2024
Irwin Jacobs & Andrew Viterbi: Qualcomm's Pioneering Founders
In 1985, Irwin Jacobs and Andrew Viterbi co-founded Qualcomm, a leading company in telecommunications and semiconductor innovation.
3 Oct 2024
Ticker symbol
ADAG
Country
🇺🇸 United States